Catalyst Pharmaceuticals, Inc. reaffirmed revenue guidance for the full-year 2024. For the year, the company expected total revenue in the range of $455 million and $475 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.14 USD | -2.36% | -3.12% | -3.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.99% | 1.91B | |
-1.62% | 89.22B | |
+2.24% | 40.49B | |
-12.97% | 32.79B | |
+63.43% | 26.23B | |
-20.71% | 14.52B | |
-7.31% | 13.09B | |
-42.60% | 11.6B | |
-12.64% | 11.5B | |
+5.54% | 8.82B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024